WuXi AppTec buys UK CRDO firm for $135 million
China’s WuXi AppTec (SHA: 603259) yesterday announced the completion of a $135 million acquisition of OXGENE, a pioneering UK-based contract research and development organization that designs and develops scalable gene therapy technologies.
This deal broadens Wuxi’s customer offerings, allowing them to provide end-to-end support in the creation of cutting-edge cell and gene therapies, from early genetic molecular research and discovery through development and cGMP manufacturing at scale for global commercialization.
The importance of this acquisition is the potential for faster, less expensive, and more accurate commercialization at scale of cell and gene therapies for patients worldwide. These changes have the potential to improve commercialization of advanced molecular therapies by multiple orders of magnitude, says WuXi AppTec, a provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze